HAE Haemonetics Corp

  1. Stocks
  2. Healthcare
  3. NYSE: HAE

Price (delayed)

$106.82

Market cap

$4.86B

P/E Ratio

51.11

Dividend/share

N/A

EPS

$2.09

Enterprise value

$5.81B

?
Relative Growth: Rel. Growth: 40
Relative Strength: Rel. Strength: 94
Relative Valuation: Rel. Valuation: 25
Relative Profitability: Rel. Profitability: 56

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital ...

Highlights
The company's quick ratio has surged by 80% YoY
The company's gross margin rose by 3.7% YoY
The equity has declined by 5% year-on-year but it is up by 5% since the previous quarter
The price to earnings (P/E) is 109% higher than the last 4 quarters average of 24.8 and 20% higher than the 5-year quarterly average of 43.4
HAE's net income is down by 41% year-on-year
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.haemonetics.com
Peers: TMO SYK BDX CERS

Key stats

What are the main financial stats of HAE

HAE stock price

How has the Haemonetics stock price performed over time
Intraday
-1.57%
1 week
0.55%
1 month
-1.82%
1 year
110.9%
YTD
33.28%
QTD
42.43%

Financial performance

How have Haemonetics's revenue and profit performed over time
Revenue
$1.35B
Gross profit
$798.15M
Operating income
$158.44M
Net income
$96.29M
Gross margin
59%
Net margin
7.1%
The net margin is down by 41% year-on-year and by 2.7% since the previous quarter
HAE's net income is down by 41% year-on-year
The operating margin has contracted by 26% YoY
The operating income is down by 26% year-on-year but it is up by 2.3% since the previous quarter

Price vs fundamentals

How does HAE's price correlate with its fundamentals

Growth

What is Haemonetics's growth rate over time

Valuation

What is Haemonetics stock price valuation
HAE P/E details
P/E
51.11
P/B
5.8
P/S
3.58
EV/EBIT
36.24
EV/EBITDA
21.49
EV/Sales
4.3
The price to earnings (P/E) is 109% higher than the last 4 quarters average of 24.8 and 20% higher than the 5-year quarterly average of 43.4
The company's EPS fell by 36% YoY
The price to book (P/B) is 64% higher than the last 4 quarters average of 3.6 and 34% higher than the 5-year quarterly average of 4.4
The equity has declined by 5% year-on-year but it is up by 5% since the previous quarter
The stock's P/S is 58% more than its last 4 quarters average of 2.3 and 21% more than its 5-year quarterly average of 3.0

Efficiency

How efficient is Haemonetics business performance
HAE's return on equity is down by 40% year-on-year
The company's return on assets fell by 39% YoY
The company's return on sales fell by 32% YoY
The company's return on invested capital fell by 30% YoY

Dividends

What is HAE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HAE.

Financial health

How did Haemonetics financials performed over time
The total assets is 55% more than the total liabilities
The company's quick ratio has surged by 80% YoY
The current ratio has soared by 79% YoY and by 4.4% from the previous quarter
The debt is 40% greater than the equity
The debt to equity has contracted by 9% from the previous quarter
The equity has declined by 5% year-on-year but it is up by 5% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.